|
시장보고서
상품코드
1983289
골수이형성증후군 치료 시장 : 약물별, 투여 경로별, 유통 채널별, 지역별Myelodysplastic Syndrome Treatment Market, By Drug, By Route Of Administration, By Distribution Channel, By Geography |
||||||
골수이형성증후군 치료 시장은 2026년에 29억 9,000만 달러로 추정되며, 2033년까지 46억 3,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 6.4%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 29억 9,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 6.40% | 예측 금액(2033년) | 46억 3,000만 달러 |
골수이형성증후군은 골수 내 미성숙한 혈액세포가 성숙하지 못하고 정상적인 혈액세포로 자라지 못하는 암의 일종입니다. 다양한 유형의 골수이형성증후군은 혈액세포와 골수의 특정 변화를 바탕으로 진단됩니다. 골수이형성증후군(MDS)은 정상적인 혈액세포가 충분히 생성되지 않는 희귀암의 일종입니다. 골수이형성이라고도 합니다. MDS에는 몇 가지 유형이 있습니다. MDS는 골수 내 세포의 일부가 이상(이형성)을 일으켜 새로운 혈액세포를 만드는 데 문제가 있는 질환입니다. 이 골수 세포에 의해 형성된 혈액 세포 중 일부는 결함이 있습니다. 결함이 있는 세포는 정상 세포보다 빨리 죽는 경우가 많고, 신체도 일부 비정상적인 혈액 세포를 파괴하기 때문에 환자의 몸에는 충분한 정상 혈액 세포가 남지 않습니다. 다양한 종류의 세포가 영향을 받을 수 있지만, 골수이형성증후군의 가장 흔한 소견은 적혈구 부족(빈혈)입니다. 치료 관련 MDS는 골수이형성증후군의 일종입니다. 이는 과거 암 치료의 화학요법이나 방사선 치료로 인해 발생합니다. 미국에서는 골수이형성증후군과 치료 관련 골수이형성증후군의 신규 진단 건수가 모두 증가하고 있습니다. 이는 고령자가 인구에서 차지하는 비율이 증가하고 있고, 암 치료 후 생존기간이 길어지고 있기 때문입니다.
시장 역학
북미, 라틴아메리카, 유럽, 아시아태평양, 아프리카 등 주요 지역에서 아자시티딘의 출시 및 승인 증가는 예측 기간 동안 골수이형성증후군 치료 시장의 아자시티딘 부문의 성장을 견인할 것으로 예상됩니다. 예를 들어, 2018년 2월, 생명공학 기업 BeiGene, Ltd.는 VIDAZ(아자시티딘 주사제)의 중국 시판 시작을 발표했습니다. VIDAZA는 중국에서 중간형 2형/고위험 골수이형성증후군(MDS), 골수모세포가 20-30%를 차지하는 급성 골수성 백혈병(AML), 만성골수성단핵성백혈병(CMML) 환자의 치료제로 승인됐습니다. 본 제품은 셀진 코퍼레이션(제약회사)의 독점적 라이선스에 따라 BeiGene이 중국에서 판매하고 있습니다.
본 보고서의 주요 특징
- 세계의 골수이형성증후군(MDS) 치료 시장을 상세히 분석했으며, 2021년을 기준 연도로 하여 예측 기간(2022-2030년)의 시장 규모와 CAGR을 조사하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 세계 골수이형성증후군(MDS) 치료 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등의 정보를 바탕으로 정리하여 전해드립니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 종류 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 골수이형성증후군(MDS) 치료 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 골수이형성증후군(MDS) 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 골수이형성증후군 치료 시장 : 약물별(2020-2033년)
제5장 세계의 골수이형성증후군 치료 시장 : 투여 경로별(2020-2033년)
제6장 세계의 골수이형성증후군 치료 시장 : 유통 채널별(2020-2033년)
제7장 세계의 골수이형성증후군 치료 시장 : 지역별(2020-2033년)
제8장 경쟁 구도
제9장 애널리스트의 제안
제10장 참고문헌과 분석 방법
KSM 26.04.20Myelodysplastic Syndrome Treatment Market is estimated to be valued at USD 2.99 Bn in 2026 and is expected to reach USD 4.63 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.99 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.40% | 2033 Value Projection: | USD 4.63 Bn |
Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. The different types of myelodysplastic syndromes are diagnosed based on certain changes in the blood cells and bone marrow. Myelodysplastic syndromes (MDS) are a type of rare blood cancers where don't have enough healthy blood cells. It is also known as myelodysplasia. There are several different types of MDS. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and have problems making new blood cells. Several of the blood cells formed by these bone marrow cells are defective. Defective cells often die earlier than normal cells, and the body also destroys some abnormal blood cells, leaving the person without enough normal blood cells. Different cell types can be affected, although the most common finding in Myelodysplastic syndromes is a shortage of red blood cells (anemia). Therapy-related MDS is a subtype of Myelodysplastic syndromes. It is caused by treatment with chemotherapy or radiation therapy for a previous cancer. In the U.S., the number of new diagnoses of Myelodysplastic syndromes and therapy-related Myelodysplastic syndromes are both rising. This is because older people make up a growing segment of the population and people now live longer after treatment for cancer.
Market Dynamics
Increasing launch and approval of Azacitidine in key regions namely North America, Latin America, Europe, Asia Pacific, and Africa etc. is expected to drive growth of Azacitidine segment of the myelodysplastic syndrome treatment market over the forecast period. For instance, in February 2018, BeiGene, Ltd. Biotechnology Company announced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is approved in China for patients with intermediate-2 / high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). It is marketed in China by BeiGene under an exclusive license from Celgene Corporation (Pharmaceutical Company).
Key features of the study
- This report provides an in-depth analysis of the global myelodysplastic syndrome (MDS) treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global myelodysplastic syndrome (MDS) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global myelodysplastic syndrome (MDS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myelodysplastic syndrome (MDS) treatment market
Market Segmentation
- Drug Insights (Revenue, USD Bn, 2026 - 2033)
- Lenalidomide
- Decitabine
- Azacitidine
- Phase 3 Drugs
- Route of Administration Insights (Revenue, USD Bn, 2026 - 2033)
- Injection
- Oral
- Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Key Players Insights
- Celgene Corporation
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Dr. Reddy's Laboratories Ltd.
- Mylan NV
- Cipla Limited
- Acceleron Pharma, Inc.
- Aprea Therapeutics
- FibroGen Inc.
- Onconova Therapeutics Inc.
- Geron
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Myelodysplastic Syndrome Treatment Market, By Drug
- Global Myelodysplastic Syndrome Treatment Market, By Route of Administration
- Global Myelodysplastic Syndrome Treatment Market, By Distribution Channel
- Global Myelodysplastic Syndrome Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global Myelodysplastic Syndrome Treatment Market, By Drug, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Lenalidomide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Decitabine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Azacitidine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Phase 3 Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
5. Global Myelodysplastic Syndrome Treatment Market, By Route of Administration, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
6. Global Myelodysplastic Syndrome Treatment Market, By Distribution Channel, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
7. Global Myelodysplastic Syndrome Treatment Market, By Region, 2020 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Acceleron Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aprea Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FibroGen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Onconova Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Geron
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
